Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GW Pharmaceuticals Ltd.
ClinicalTrials.gov Identifier:
NCT01323465
First received: March 23, 2011
Last updated: June 13, 2013
Last verified: June 2013

March 23, 2011
June 13, 2013
February 2008
March 2008   (final data collection date for primary outcome measure)
  • Pharmacokinetic analysis - Cmax of Sativex® alone and of Sativex® with concomitant administration of rifampicin, ketoconazole, and omeprazole [ Time Frame: Up to Day 8 ] [ Designated as safety issue: No ]
  • Pharmacokinetic analysis - AUC(0-t) of Sativex® alone and of Sativex® with concomitant administration of rifampicin, ketoconazole, and omeprazole [ Time Frame: Up to day 8 ] [ Designated as safety issue: No ]
  • Pharmacokinetic analysis - AUC(0-inf) of Sativex® alone and of Sativex® with concomitant administration of rifampicin, ketoconazole, and omeprazole [ Time Frame: Up to Day 8 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01323465 on ClinicalTrials.gov Archive Site
Adverse Events [ Time Frame: Up to follow up, Day 14 ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex
A Phase I, Open-label, Randomised, Crossover Study in 3 Parallel Groups to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex in Healthy Volunteers

Study to assess the effect of rifampicin, ketoconazole and omeprazole on the pharmacokinetics of a single dose of Sativex and to evaluate the safety of Sativex when given in combination with these other drugs.

An open-label, randomised, crossover, drug interaction study. Subjects were divided into three groups and within each group, subjects were randomised to one of two treatment sequences. Subjects received 4 sprays of Sativex alongside either doses of rifampicin, ketoconazole or omeprazole.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
  • Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4
  • Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4
  • Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor.
  • Drug: Sativex and rifampicin
    Single dose of 4 sprays Sativex on Day 1, Rifampicin 2 x 300 mg capsules on Days 2-10, Sativex dose of 4 sprays and rifampicin 2 x 300 mg capsules on Day 11.
  • Drug: Sativex and rifampicin
    Rifampicin 2 x 300 mg capsules on Days 1-9, Sativex x 4 sprays and rifampicin 2 x 300 mg capsules on Day 10, Single dose of Sativex 4 sprays on Day 18.
  • Drug: Sativex and ketoconazole
    Single dose of 4 sprays Sativex on Day 1, ketoconazole 2 x 200 mg tablets on Days 2-5, Sativex x 4 sprays and ketoconazole 2 x 200mg on Day 6.
  • Drug: Sativex and ketoconazole
    Ketoconazole 2 x 200 mg tablets on Days 1-4, Sativex x 4 sprays and ketoconazole 2 x 200 mg tablets on Day 5, Single dose of 4 sprays Sativex on Day 9.
  • Drug: Sativex and omeprazole
    Single dose of 4 sprays of Sativex on Day 1 Omeprazole 2 x 20 mg on Days 2-6. Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 9.
  • Drug: Sativex and omeprazole
    Omeprazole 2 x 20 mg on Days 1-5, Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 6, Single dose of 4 sprays Sativex on Day 9.
  • Experimental: Sequence 1A
    Sativex and rifampicin
    Intervention: Drug: Sativex and rifampicin
  • Experimental: Sequence 1B
    Sativex and rifampicin
    Intervention: Drug: Sativex and rifampicin
  • Experimental: Sequence 2C
    Sativex and ketoconazole
    Intervention: Drug: Sativex and ketoconazole
  • Experimental: Sequence 2D
    Sativex and ketoconazole
    Intervention: Drug: Sativex and ketoconazole
  • Experimental: Sequence 3E
    Sativex and omeprazole
    Intervention: Drug: Sativex and omeprazole
  • Experimental: Sequence 3F
    Sativex and omeprazole
    Intervention: Drug: Sativex and omeprazole
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
March 2008
March 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy male subjects between 18 and 45 years of age (inclusive).
  • Subjects body mass index was between 18-30 kg/m2 (inclusive) as calculated by: Weight (kg)/height (m2).
  • No clinically significant abnormal findings on the physical examination, ECG, medical history, or clinical laboratory results during screening.
  • Subjects were to, in the opinion of the investigator, have no clinically significant abnormal findings of renal and hepatic function as determined by serum creatinine, total bilirubin, and transaminase levels.
  • Subjects were to be non-users of tobacco products (minimum of 6 months prior to the start of the study).
  • Subjects were to have a negative screen for HIV I and II, HBsAg. and antibody to hepatitis C.
  • Subjects were to have a negative urine screen for alcohol, drugs of abuse (screening only), and cotinine.
  • Subjects were to use an appropriate barrier method of contraception (condom and spermicide) in addition to having their female partner use another form of barrier contraception (e.g. female condom or occlusive cap [diaphragm or cervical vault/caps] with spermicide) during the study and for 3 months following administration of the study drug.
  • Subjects were to be able to comply with the protocol and the restrictions and the assessments therein.
  • Subjects were to give voluntary written informed consent to participate in the trial.

Exclusion Criteria:

  • Subjects were not to have a history or presence of significant cardiovascular, pulmonary, hepatic, renal, haematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease.
  • Subjects were not to have any history or presence of family history of schizophrenia, other psychotic illness, severe personality disorder, depression, or other significant psychiatric disorder.
  • Subjects were not to have a postural drop of 20 mmHG or more in systolic blood pressure at screening.
  • Subjects were not to have participated in a previous clinical trial within 90 days prior to study initiation.
  • Subjects were not to have donated plasma within 90 days prior to study initiation.
  • Subjects were not to have donated blood within 90 days prior to study initiation.
  • Subjects were not to have had an abnormal diet or substantial changes in eating habits within 30 days prior to study initiation.
  • Subjects were not to have had treatment with any known enzyme-altering agents (barbiturates, phenothiazines, cimetidine etc.) within 30 days prior to or during the study.
  • Subjects were to have no history of known hypersensitivity or idiosyncratic reaction to the study drugs or related compounds.
  • Subjects were not to use any prescription medication within 14 days prior to or during the study.
  • Subjects were not to use any over-the-counter medication within 7 days prior to or during the study.
  • Subjects were not to have a history of alcohol or drug abuse within 2 years prior to the study (subjects with a history of previous use of cannabis were not excluded unless they had used cannabis or cannabinoid based medicine within 30 days prior to study drug administration or were unwilling to abstain for the duration of the study).
Male
18 Years to 45 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT01323465
GWCP0602
No
GW Pharmaceuticals Ltd.
GW Pharmaceuticals Ltd.
Not Provided
Not Provided
GW Pharmaceuticals Ltd.
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP